solithromycin + ceftriaxone + azithromycin
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Urogenital Gonorrhea
Conditions
Uncomplicated Urogenital Gonorrhea
Trial Timeline
Aug 1, 2014 → Feb 22, 2017
NCT ID
NCT02210325About solithromycin + ceftriaxone + azithromycin
solithromycin + ceftriaxone + azithromycin is a phase 3 stage product being developed by Allergy Therapeutics for Uncomplicated Urogenital Gonorrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT02210325. Target conditions include Uncomplicated Urogenital Gonorrhea.
What happened to similar drugs?
1 of 5 similar drugs in Uncomplicated Urogenital Gonorrhea were approved
Approved (1) Terminated (0) Active (4)
🔄Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02210325 | Phase 3 | Completed |
Competing Products
13 competing products in Uncomplicated Urogenital Gonorrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZY19489 + Ferroquine (FQ) + Placebo | Zydus Lifesciences | Phase 1 | 36 |
| KLU156 + Coartem | Novartis | Phase 3 | 40 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 38 |
| INE963 | Novartis | Phase 2 | 35 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 35 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 35 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 42 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 35 |
| Co-artemether | Novartis | Approved | 43 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 37 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg | Amneal Pharmaceuticals | Phase 3 | 37 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 29 |
| Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin | Iterum Therapeutics | Phase 3 | 30 |